Clinical Trial for Triple Negative.

Traci-----TripNeg

Hi Trip Neg Sisters,

I just got this email. Thought I would share.

Hugs, Traci 

At some point in the past, you used an online tool called the Breast Cancer Profiler. At that time, you indicated that you would be interested in being contacted by NexCura, A Thomson Reuters Business, which operates the Cancer Profiler Tools, with information about clinical trials relevant to your disease. We thought this additional information would be of interest to you.

Today we are notifying you of a clinical trial that is currently enrolling patients with triple negative breast cancer. Triple negative breast cancer is defined as breast cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. This study is being conducted at numerous sites throughout the United States and worldwide.

If you answer "yes" to all of the questions below, you may qualify for this study.

• Are you 18 years of age or older?
• Have you had invasive cancer of the breast?
• Have you been diagnosed as having triple negative breast cancer (breast cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative)?
• Has your surgery been completed for early breast cancer (lumpectomy or mastectomy)?

To learn more about this study and to find out whether you may be eligible to participate, please call toll-free, 1-800-338-9910.

---

If you have questions about why you received this e-mail please contact:

NexCura Clinical Trial Services
1215 Fourth Avenue, Suite 1925,
Seattle, WA 98161
Email: clinicaltrials@education.nexcura.com
Phone: 1-877-422-3228

If you wish to review NexCura's Privacy Statement, visit:
http://www.nexcura.com/nexcura/Nexcura_Privacy.asp



You have received this e-mail as a result of your request for information when you registered with NexCura, Inc. You may unsubscribe from this e-mail notification service at any time by going to the following page: http://www.nexcura.com/EU.asp?ESubId=0E9895BF6D4A4F7C8A61D5616CD109A8_%26%25%25%27%26%23cb
NexCura will not release your e-mail address or other personally identifying information.